“Make biologics in India” slogan reverberates in BIO

The large Indian biotech delegation unleashed the “Make in India” campaign showcasing the changed regulatory and governance regime that is making the country business-friendly on a day the world tried to attract biotech industry attention at BIO International


Philadelphia, 17 June 2015: As nations and various states in the US competed for biotech industry attention at the annual BIO International Convention here, India too was all over the place with four back-to-back sessions showcasing the research and innovation capabilities, Make in India initiatives to ensure ease of business, regulatory changes to make things easy for biotech companies and above all the talent powerhouse that the country is.

" There is a global capacity shortage in biological manufacturing building up as demand goes up due to increased access. India has shown world class biological manufacturing can be done in vaccines and other therapeutic products. Now India is a compelling place to invest and fill the rising demand gap," said Dr Kiran Mazumdar-Shaw, Chairman, Biocon and head of CII's India biotech delegation.

In fact, she showcased India's biotech capabilities at four different sessions during the day and answered a wide range of questions from potential investors, flanked by senior government officials and industry leaders. In the absence of S&T minister, Dr Harsh Vardhan's at the convention, Dr Kiran filled in admirably.

Two senior officials, Mr Sreeshan Raghavan from Department of Biotechnology and Dr M Ariz Ahammed from the Department of Pharmaceuticals, rolled out the highlights of the Make in India program and traced the recent regulatory changes that are removing some of the hurdles in the path of clinical trials in India in the last three years.

" A time bound approval process has been put in for clinical trials," said Dr Ahammed. Similarly, the governments has also streamlined the drug approval process by roping in more than 150 subject matter experts instead of a single Drug Advisory Committee to clear proposals quicker.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email